Vir Biotech, GSK Dose Patient in NIH-Sponsored Trial of Covid-19 Treatment
2020年12月18日 - 08:30AM
Dow Jones News
By Stephen Nakrosis
Vir Biotechnology Inc. and GlaxoSmithKline PLC on Thursday said
the first patient had been dosed in a trial to evaluate VIR-7831 to
treat hospitalized adults with Covid-19.
The companies said the "randomized, placebo-controlled,
multicenter, global Phase 3 trial will investigate the safety and
efficacy of VIR-7831 in hospitalized adults with Covid-19."
The trial is being carried out under the auspices of the
National Institutes of Health's Accelerating Covid-19 Therapeutic
Interventions and Vaccines, or ACTIV, Program Phase 3, the
companies said. "ACTIV-3 is one of several ongoing trials in the
NIH's ACTIV program, an NIH-led public-private partnership designed
to accelerate development of the most promising treatments and
vaccine candidates for Covid-19," the companies said.
George Scangos, the chief executive officer of Vir, said,
"Recent data suggest that the neutralizing activity of antibodies
may be insufficient to protect hospitalized adults from the most
severe consequences of Covid-19. We are hopeful that the
differentiating factors and broad anti-coronavirus activity of
VIR-7831 may allow it to help those patients and add to our
preparedness for related coronaviruses that could emerge in the
future."
In addition to the Phase 3 ACTIV-3 trial, VIR-7831 is being
evaluated in the global Phase 2/3 COMET-ICE trial for the early
treatment of Covid-19 in adults at high risk of hospitalization,
the companies said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 17, 2020 18:15 ET (23:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 2 2024 まで 3 2024
Gsk (LSE:GSK)
過去 株価チャート
から 3 2023 まで 3 2024